You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

Citation Tools

Article menu

Download PDFPDF

XML
Immunotherapy biomarkers
Original research
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Jiménez-Cortegana C, Palazón-Carrión N, Martin Garcia-Sancho A Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA), Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA), On behalf of the Spanish Lymphoma Oncology Group (GOTEL) and the Spanish Group for Immunobiotherapy of Cancer (GÉTICA), et al
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial
Journal for ImmunoTherapy of Cancer 2021;9:e002323. doi: 10.1136/jitc-2020-002323